Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 12 (December)

1. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer.
   Med Hypotheses, 70(1): 122-7. [Abstract] [Full-text]
2. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
   Med Hypotheses, 70(1): 128-36. [Abstract] [Full-text]
3. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice.
   Am J Respir Crit Care Med, 176(12): 1243-50. [Abstract] [Full-text]
4. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
   Blood, 110(13): 4614-7. [Abstract] [Full-text]
5. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
   Int J Cancer, 122(3): 711-8. [Abstract] [Full-text]
6. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
   Int J Cancer, 122(3): 664-71. [Abstract] [Full-text]
7. Targeted chronic myeloid leukemia therapy: Seeking a cure.
   Am J Health Syst Pharm, 64(24): S9-15. [Abstract] [Full-text]
8. New strategies in controlling drug resistance in chronic myeloid leukemia.
   Am J Health Syst Pharm, 64(24): S16-21. [Abstract] [Full-text]
9. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
   J Clin Invest, 117(12): 4044-4054. [Abstract] [Full-text]
10. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
    J Clin Invest, 117(12): 3650-3. [Abstract] [Full-text]
11. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Clin Cancer Res, 13(23): 7080-5. [Abstract] [Full-text]
12. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Haematologica, 92(12): 1723-4. [Abstract] [Full-text]
13. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
    Haematologica, 92(12): 1721-2. [Abstract] [Full-text]
14. Part II: management of resistance to imatinib in chronic myeloid leukaemia.
    Lancet Oncol, 8(12): 1116-28. [Abstract] [Full-text]
15. The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective.
    Onkologie, 30(12): 645-8. [Abstract] [Full-text]
16. FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.
    Biochim Biophys Acta, 1785(1): 63-84. [Abstract] [Full-text]
17. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Leuk Lymphoma, 48(12): 2310-22. [Abstract] [Full-text]
18. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Cancer Genet Cytogenet, 180(1): 60-4. [Abstract] [Full-text]
19. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
    Pediatr Blood Cancer, 50(2): 254-8. [Abstract] [Full-text]
20. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Pediatr Blood Cancer, 50(2): 386-8. [Abstract] [Full-text]
21. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.
    Eur J Hum Genet, 16(1): 79-88. [Abstract] [Full-text]
22. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells.
    Oncogene, 26(57): 7904-8. [Abstract] [Full-text]
23. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Cancer Chemother Pharmacol, 61(3): 365-76. [Abstract] [Full-text]
24. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Cancer Chemother Pharmacol, 61(3): 515-24. [Abstract] [Full-text]
25. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.
    FEBS Lett, 581(30): 5897-903. [Abstract] [Full-text]
26. Cytostatic drugs differentially affect phenotypic features of porcine coronary artery smooth muscle cell populations.
    FEBS Lett, 581(30): 5847-51. [Abstract] [Full-text]
27. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Lancet, 370(9604): 2011-9. [Abstract] [Full-text]
28. Secondary c-kit Mutation in a Recurrent Gastrointestinal Stromal Tumor Under Long-Term Treatment with Imatinib Mesylate: Report of a Case.
    Surg Today, 38(1): 65-7. [Abstract] [Full-text]
29. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.
    Cancer Res, 67(24): 11576-84. [Abstract] [Full-text]
30. Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation.
    J Pharmacol Exp Ther, 324(1): 128-38. [Abstract] [Full-text]
31. Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib.
    Clin Cancer Res, 13(24): 7394-400. [Abstract] [Full-text]
32. Targeted therapy in chronic myeloid leukemia.
    Expert Rev Anticancer Ther, 8(1): 99-110. [Abstract] [Full-text]
33. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Ann Oncol, 19(1): 173-7. [Abstract] [Full-text]
34. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
    Gynecol Oncol, 108(1): 182-90. [Abstract] [Full-text]
35. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
    J Clin Oncol, 26(1): 106-11. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.